US EditionHims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration
Hims & Hers will sell Novo Nordisk’s FDA-approved GLP-1 drugs on its U.S. telehealth platform after ending compounded drug sales amid rising demand and regulatory pressure.
- On Monday, Novo Nordisk dropped its lawsuit after Hims agreed to sell Wegovy and Ozempic, with CEO Mike Doustdar saying, 'We have decided to drop the current court proceedings...'
- Hims had been selling compounded semaglutide using a regulatory loophole and planned an off-brand Wegovy pill priced at $49, prompting Novo Nordisk to threaten legal action last month.
- Shares reacted after Friday's move when Hims & Hers shares jumped more than 40% in Monday morning trading and rose nearly 40% within an hour, while Novo's stock increased 1.7%.
- Novo warned it may refile the lawsuit, while Hims said existing patients on compounding semaglutide can transition to FDA-approved medicines when clinically appropriate.
- Semaglutide's patent is protected in the U.S. until 2032, and with supply constraints easing, the deal helps Hims avoid recent regulatory problems and recoup losses earlier this year.
83 Articles
83 Articles
Hims & Hers to partner with Novo Nordisk and stop selling compounded GLP-1s
Telehealth company Hims & Hers on Monday announced a "strategic shift" in its business model, partnering with pharmaceutical company Novo Nordisk to sell its blockbuster GLP-1 medication and stop selling the "copycat" compounded versions it has long advertised. In a press release, Hims & Hers said it will "no longer advertise compounded GLP-1 offerings on...
Hims & Hers, Novo End Dispute and Announce Collaboration on Wegovy and Ozempic
Novo Nordisk and telehealth company Hims & Hers have ended their dispute over weight loss medications, the companies said on March 9 as they announced a new partnership. Novo is dropping a patent infringement lawsuit against Hims & Hers, the Denmark-based pharmaceutical company said in a statement. And Novo’s weight loss medications—Ozempic and Wegovy, both approved by the Food and Drug Administration—will be offered through Hims & Hers starting…
The actions of the Hims & Hers Health telehealth group are skyrocketing this Monday after the Danish Novo Nordisk put an end to her public dispute with the company through an agreement to sell her weight-loss drugs on the Hims platform.
Novo Nordisk Ends Lawsuit, Collaborates With Hims & Hers to Sell Semaglutide
(MedPage Today) -- Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see branded semaglutide (Ozempic, Wegovy) products sold through the...
Coverage Details
Bias Distribution
- 74% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
